Table 4. Characteristics of 53 patients receiving anticoagulation therapy

	n = 53 (%)
Type of anticoagulant, n (%)
LMWH	44 (83.0)
UFH followed by oral vitamin K antagonists	4 (7.6)
UFH followed by DOAC	4 (7.6)
DOAC (Rivaroxaban)	1 (1.8)
Withholding, n (%)	14 (26.2)
Reasons for withholding, n (%)
Major bleeding	0 (0)
Minor bleeding	2 (3.8)
Thrombocytopenia	3 (5.7)
Patient’s preference	9 (17.0)

Abbreviations: DOAC = direct oral anticoagulant; LMWH = low molecular weight heparin; UFH = unfractionated heparin